Glupride M2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, improving insulin sensitivity. The combination of these two agents provides complementary mechanisms of action, resulting in improved glycemic control in patients inadequately controlled by diet and exercise alone. Glupride M2 Tablet PR is indicated for adult patients with type 2 diabetes who require dual therapy to achieve target blood glucose levels. It is important to initiate treatment with appropriate lifestyle modifications, including diet and exercise. The extended-release formulation allows for once-daily dosing, improving patient compliance and maintaining steady plasma drug concentrations. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often diminish with continued use. Hypoglycemia is a potential risk due to glimepiride; therefore, monitoring blood glucose levels regularly is essential. Glupride M2 Tablet PR should be used cautiously in patients with renal or hepatic impairment and is contraindicated in those with severe renal dysfunction, metabolic acidosis, or hypersensitivity to its components.